Study Examining Use of Ultra-Thick Amniotic Membrane in Complex Ureteral Reconstruction Presented at 2025 American Urological Association Conference

Results Demonstrate Effectiveness of BioTissue Surgical’s Clarix® 1K

MIAMI, April 22, 2025—New research examining the clinical outcomes of robotic ureteral reconstruction with adjunctive ultra-thick Amniotic Membrane will be presented this week at the 2025 American Urological Association Conference in Las Vegas. The prospective review highlights the benefits of using BioTissue Surgical’s Clarix® 1K, a cryopreserved, ultra-thick human Amniotic Membrane allograft for surgical applications.

In the study, researchers evaluated outcomes from 17 patients (nine women and eight men) who had undergone robotic-assisted laparoscopic uretero-ureterostomy using cryopreserved ultra-thick human amniotic Membrane (Clarix® 1K). At a one-year post-operative follow-up, 88% of patients reported symptomatic improvement, and radiographic improvement was observed in 76% of patients. Mutahar Ahmed, MD, and his co-investigators, concluded that the use of Clarix® 1K in ureteral reconstruction is a safe and effective alternative to autologous grafting for medium length ureter strictures in complex patient populations.

“The work by Dr. Ahmed and his colleagues shows the benefits of amniotic tissue in yet another surgical application,” said Ted Davis, CEO of BioTissue. “We are proud to partner with practitioners in a range of specialties, including urology, to help improve patient outcomes.”

The presentation, “Clinical Outcomes of Robotic Ureteral Reconstruction with Adjunctive Ultra-Thick Amniotic Membrane” will be presented on Sunday, April 27 from 3:30 p.m. to 5:30 p.m. at the American Urological Association Conference at the Venetian Convention & Expo Center.

For more information on BioTissue and Clarix® 1K, visit BioTissue.com/surgical.

# # #

About BioTissue Holdings Inc.
BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of Cryopreserved Amniotic Membrane (CAM) products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple investigational new drug clinical trials as the company pursues Biologic License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 900,000 human implants with its products and published over 400 peer-reviewed publications supporting BioTissue’s platform technology. Learn more at biotissue.com.

Media Contact

Wendy Boyce
McDougall Communications for BioTissue Holdings Inc.

[email protected] or (585) 752-5805